Compare TLF & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | MRKR |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 22.5M |
| IPO Year | 2006 | 2010 |
| Metric | TLF | MRKR |
|---|---|---|
| Price | $2.44 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 37.0K | ★ 66.7K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 32.05% | N/A |
| EPS Growth | ★ 1122.22 | 33.61 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $76,324,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | $80.67 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.20 | $0.81 |
| 52 Week High | $3.78 | $4.07 |
| Indicator | TLF | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 48.38 |
| Support Level | $2.26 | $1.35 |
| Resistance Level | $2.44 | $1.44 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 83.39 | 31.71 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).